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Objectives: To estimate the clinical and economic trade-offs involved in using the 
molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown 
Primary (CUP). MethOds: A decision-analytic model was developed to estimate 
the lifetime clinical and economic outcomes of incorporating the EPICUP assay 
compared with other molecular assays (CancerTYPE ID, Cancer Origin Test and 
ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary cancer 
sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma histo-
logical subtype. Results are presented as incremental cost-effectiveness ratio (ICER, 
cost per quality-adjusted life-years [QALY] gained) from the USA Health Payers 
perspective. Model inputs were based on a case-control study of EPICUP, published 
literature, Surveillance Epidemiology and End Results database and a clinical expert 
panel. Results: Based on a price of USD3,500 for EPICUP and for a willingness to 
pay USD100,000, EPICUP is cost-effective (vs. CancerTYPE ID, Cancer Origin Test and 
ResponseDX: Tissue of Origin Test) in all tumors analyzed, ranging between 80% and 
100% of the simulations. EPICUP increased the proportion of patients treated cor-
rectly, decreased the proportion of patients treated with an empiric approach, and 
increased the quality-adjusted overall survival. For a willingness to pay USD50,000 
EPICUP is cost-effective in breast, colon, pancreas, lung (NSCLC) and prostate can-
cer, again ranging between 80% and 100% of the simulations. These findings were 
robust across deterministic and probabilistic sensitivity analyses. cOnclusiOns: 
EPICUP assay for diagnosing the primary tumor in CUP patients is a cost-effective 
approach in breast, colon, pancreas, lung (NSCLC), hepatocellular and prostate can-
cer in comparison with other alternatives available, while improving patient care.
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Objectives: To assess the health effectiveness, cost and cost-effectiveness of dif-
ferent oral anticoagulation therapies in China including warfarin plus International 
Normalized Ratio (INR) test in hospital labs (Lab test), warfarin plus patient 
self-test (PST) with point of care device, and novel anticoagulant (Dabigatran) 
alone. MethOds: A Markov model containing four states (no complication, haem-
orrhagic event, thrombotic event and death) was developed to account for long term 
cost and outcomes of warfarin/novel anticoagulant users including atrial fibrilla-
tion patients and deep venous thrombosis patients. Only direct medical cost was 
taken into consideration, covering expenses of drugs, OAT monitoring and compli-
cation management. Both clinical and economic parameters were mainly derived 
from literatures. Results: The hospital lab test pattern achieved 7.46 LYs and 4.43 
QALYs with a total cost of CNY 28,277 (USD 4,561), while the PST pattern obtained 
a prolonged 8.79 LYs and 5.30 QALYs with the larger amount of cost, CNY 45,992 
(USD 7,418). Comparably, the novel anticoagulant pattern acquired 8.08 LYs and 
4.87 QALYs and the cost was significant higher reaching CNY 99,545 (USD 16,056), 
dominated by PST pattern due to shortened QALYs while increased cost. The ICER of 
PST versus hospital lab test came to CNY 20,363 (USD 3,284) per QALY gained, lower 
than China GDP per capita in 2014 (CNY 42,900). Sensitivity analysis demonstrated 
the results were not sensitive to main indicators, including utility in different health 
status, complication probability and disease management cost. cOnclusiOns: 
Compared with OAT management in hospital laboratory, PST can generate more 
QALYs by reducing the risk of major thrombotic and bleeding events with acceptable 
incremental cost, which turns to be the most cost effective among the 3 patterns 
and demonstrates promising future in OAT management.
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Objectives: To estimate the clinical and economic trade-offs involved in using the 
molecular assay EPICUP to aid in identifying the primary site in Cancer of Unknown 
Primary (CUP). MethOds: A decision-analytic model was developed to estimate the 
lifetime clinical and economic outcomes of incorporating the EPICUP assay com-
pared with standard care and other molecular assays (CancerTYPE ID, Cancer Origin 
Test and ResponseDX: Tissue of Origin Test). The analysis was limited to 6 primary 
cancer sites (breast, colon, pancreas, lung, liver and prostate) for adenocarcinoma 
histological subtype. Results are presented as incremental cost-effectiveness ratio 
(ICER, cost per quality-adjusted life-years [QALY] gained) from the Spanish National 
Health System (NHS) perspective. Model inputs were based on a case-control study 
of EPICUP, published literature, Surveillance Epidemiology and End Results database 
and, a clinical expert panel. Results: Based on a price of € 3,000 for EPICUP, the 
cost per QALY gained with EPICUP was € 3,878 versus CancerTYPE ID and € 3,406 
versus Cancer Origin Test in breast cancer; € 5,889 and € 7,186, respectively, in colon 
cancer; € 4,294 and € 23,937, respectively, in pancreatic cancer; € 7,188 and € 16,840, 
respectively, in NSCLC; € 784 and € 20,444, respectively, in hepatocellular cancer; and 
Objectives: To develop an economic evaluation to compare individually and vial-
packaged strips for glucose monitoring. MethOds: A simple decision tree model was 
developed using Excel to compare the costs of using individual vs. vial-packaged strips 
in a hospital setting. The decision tree described costs and consequences associated 
with two main parameters: risk of nosocomial infection due to the contamination 
of strips and risk of hypoglycemia/hyperglycemia due to an error in the determina-
tion of glycemia induced by the storage conditions of the strips. For each alternative 
(IP and VP), a simulated cohort of 1000 patients went through the tree accounting for 
costs and effects, and the results were expressed as hypoglycemic events, nosoco-
mial infection events, use/waste of strips and ICER. Sources of parameters is wide 
and uncertainty is high. Due to the lack of information about certain parameters, a 
group of assumptions were made .The risk of measurement error using contaminated 
strips was modelled to account for hypoglycaemic events. Uncertainty was tested 
using one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). 
Cost-effectiveness acceptability curve with a threshold of 25.000€ /QALY was drawn. 
Probabilistic results were depicted using a CE plane. Results: Individual packaged 
strips save money (1,162 € per patient) and get more QALYs (0.023 per patient), which 
confers a dominant position to individual packaged strips with 11% less nosocomial 
events, 10 times less hypoglycemic events (53 vs 655) and 6% reduction in the use of 
strips. PSA shows results in the same direction with a 64% probability of being cost-
effective under a threshold of 25,000 € (from 82% at 0 € and keeping the difference 
over 25,000 € ). cOnclusiOns: Under the assumption of wrong measurements due 
to bad storage conditions, the use of individual packaged strips is a dominant option 
over vial-packaged strips, reducing costs by a 25%.
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Objectives: To compare the effectiveness and costs in the Colombian setting (and 
estimate the incremental cost-effectiveness ratio ICER) of the most commonly 
used schemes for screening and diagnosis of type 2 diabetes mellitus in local adult 
population. MethOds: We evaluated four possible schemes, all involved fasting 
blood sugar test, two with and two without previous screening with the FINDRISC 
scale; and, in a second step, using either the oral glucose tolerance, or glycosylated 
hemoglobin tests, for confirmation of diagnosis. We designed a decision tree model 
with correctly identified cases as the main effectiveness outcome (estimated for 
Colombia from a global systematic literature review). Direct medical costs were 
estimated from the third party payer perspective (healthcare system), in Colombian 
pesos for 2014 (1 € = COP 2,660). Base cases, analyzed and validated by multidis-
ciplinary expert panel, were used for resource estimation. Official cost databases 
and tariff manuals were then applied to estimate costs. No discount rates were 
applied. Univariate and probabilistic sensitivity analyses were performed. Results: 
The schemes that used glycosylated hemoglobin test for confirmation were domi-
nated. For a cohort of 1,000 people, the strategy of FINDRISC plus fasting blood 
sugar test plus oral glucose tolerance reported 969 correctly identified cases with 
a total cost of € 7,306; while fasting blood sugar test plus oral glucose tolerance 
detected 983 at a cost of € 10,880. Comparing these two schemes, the incremental 
cost effectiveness ratio is € 255. Sensitivity analyses did not significantly affect the 
results. cOnclusiOns: This study suggests that the scheme FINDRISC plus fast-
ing blood sugar test plus oral glucose tolerance is the most appropriate strategy for 
screening and diagnosis of type 2 diabetes in Colombia.
PMD68
A Pct-AlgorithM to guiDE Antibiotic thErAPy in PAtiEnts 
hosPitAlizED with coPD ExAcErbAtions lEADs to nEt cost sAvings by 
rEDucing frEquEncy AnD DurAtion of Antibiotic usE As coMPArED to 
currEnt PrActicE
Van der Maas M1, Steuten L2
1Panaxea B.V., Enschede, The Netherlands, 2Fred Hutchinson Cancer Research Center / University 
of Washington & Panaxea bv, Seattle, WA, USA
Objectives: Antibiotics are often recommended as treatment for patients with 
COPD exacerbations. However, in many cases COPD exacerbations are not caused by 
a bacterial inflammation and antibiotics are prescribed unnecessary. Procalcitonin 
(PCT) is a biomarker with good specificity to distinguish bacterial from non-bacte-
rial inflammations. It can prevent unnecessary antibiotic prescriptions and reduce 
duration of antibiotic therapy. The goal of this study is to compare the health and 
economic consequences of using a PCT-algorithm compared to current practice in 
hospitalized patients with COPD exacerbations. MethOds: A decision tree was 
developed, comparing the expected costs and effects of the PCT-algorithm to cur-
rent practice in the UK, Germany and the Netherlands. The time horizon of the 
model captures the length of hospital stay and a societal perspective was adopted. 
Model input data are based on a systematic literature research, country specific cost 
data sources and expert opinions. The primary health outcome was the duration 
of antibiotic therapy; the incremental cost-effectiveness ratio was defined as the 
incremental costs per antibiotic day avoided. Results: Using a PCT-algorithm is 
expected to be cost-saving and more effective compared to current practice in all 
three countries. The incremental cost savings per antibiotic day avoided range from 
€ 125 in Germany and € 90 in the Netherlands, to € 52 in the UK. Probabilistic sensi-
tivity analyses showed that the PCT-algorithm tends to dominate current practice, 
though decision uncertainty remains (Germany: 58%, UK: 57%, the Netherlands: 
58%). Duration of hospital stay at baseline is the driver of the expected cost-savings 
in all three countries while reduction in antibiotic days drives the incremental effec-
tiveness of the PCT-algorithm. cOnclusiOns: A PCT-algorithm is a cost-effective 
way to guide the initiation and duration of antibiotic therapy when compared to 
current practice in COPD patients hospitalized with an exacerbation.
